Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 2
2013 2
2014 4
2016 3
2017 6
2018 2
2019 7
2020 7
2021 9
2022 11
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Region-specific DNA hydroxymethylation along the malignant progression of IDH-mutant gliomas.
Hana T, Mukasa A, Nomura M, Nagae G, Yamamoto S, Tatsuno K, Ueda H, Fukuda S, Umeda T, Tanaka S, Nejo T, Kitagawa Y, Yamazawa E, Takahashi S, Koike T, Kushihara Y, Takami H, Takayanagi S, Aburatani H, Saito N. Hana T, et al. Among authors: takayanagi s. Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16127. Online ahead of print. Cancer Sci. 2024. PMID: 38433527 Free article.
Glioblastoma with high O6-methyl-guanine DNA methyltransferase expression are more immunologically active than tumors with low MGMT expression.
Kushihara Y, Tanaka S, Kobayashi Y, Nagaoka K, Kikuchi M, Nejo T, Yamazawa E, Nambu S, Kugasawa K, Takami H, Takayanagi S, Saito N, Kakimi K. Kushihara Y, et al. Among authors: takayanagi s. Front Immunol. 2024 Jan 15;15:1328375. doi: 10.3389/fimmu.2024.1328375. eCollection 2024. Front Immunol. 2024. PMID: 38288307 Free PMC article.
Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
Neyazi S, Yamazawa E, Hack K, Tanaka S, Nagae G, Kresbach C, Umeda T, Eckhardt A, Tatsuno K, Pohl L, Hana T, Bockmayr M, Kim P, Dorostkar MM, Takami T, Obrecht D, Takai K, Suwala AK, Komori T, Godbole S, Wefers AK, Otani R, Neumann JE, Higuchi F, Schweizer L, Nakanishi Y, Monoranu CM, Takami H, Engertsberger L, Yamada K, Ruf V, Nomura M, Mohme T, Mukasa A, Herms J, Takayanagi S, Mynarek M, Matsuura R, Lamszus K, Ishii K, Kluwe L, Imai H, von Deimling A, Koike T, Benesch M, Kushihara Y, Snuderl M, Nambu S, Frank S, Omura T, Hagel C, Kugasawa K, Mautner VF, Ichimura K, Rutkowski S, Aburatani H, Saito N, Schüller U. Neyazi S, et al. Among authors: takayanagi s. Acta Neuropathol. 2024 Jan 24;147(1):22. doi: 10.1007/s00401-023-02668-9. Acta Neuropathol. 2024. PMID: 38265489 Free PMC article.
Case report and literature review: exploration of molecular therapeutic targets in recurrent malignant meningioma through comprehensive genetic analysis with Todai OncoPanel.
Ohara K, Miyawaki S, Nakatomi H, Okano A, Teranishi Y, Shinya Y, Ishigami D, Hongo H, Takayanagi S, Tanaka S, Shinozaki-Ushiku A, Kohsaka S, Kage H, Oda K, Miyagawa K, Aburatani H, Mano H, Tatsuno K, Saito N. Ohara K, et al. Among authors: takayanagi s. Front Neurol. 2023 Nov 23;14:1270046. doi: 10.3389/fneur.2023.1270046. eCollection 2023. Front Neurol. 2023. PMID: 38073632 Free PMC article.
67 results